Commonwealth Bank of Australia (ASX: CBA) and CSL Ltd (ASX: CSL) are two of the highest-quality businesses on the ASX.
They are also both trading well below their recent highs.
CBA shares are down around 18% from their 52-week high, while CSL shares have fallen to multi-year lows after a very difficult period for the biotechnology giant.
I rate both as buys. But if I could only choose one today, I would lean toward CSL.
Image source: Getty Images
The case for CBA shares
CBA is still the highest-quality major bank in Australia, in my view.
It has a powerful deposit franchise, a huge customer base, strong digital capability, and a brand that gives it an advantage across home loans, transaction banking, business banking, and wealth-adjacent services.
The bank has consistently shown over many years that it can generate strong profits, support large dividends, and trade at a premium valuation relative to its peers. Investors trust the business for good reason.
In my opinion, the recent share price fall has simply made the buying case more appealing.
CBA had been priced very strongly, and the market may have been looking for an excuse to take some heat out of the valuation. After an 18% fall from its high, the risk-reward looks better than it did a few months ago.
For investors wanting quality, income, and exposure to Australia's largest bank, CBA remains a share I would be happy to own.
Why CSL shares get my vote
CSL is a very different situation.
Sentiment toward the biotechnology giant is incredibly weak. The shares are at multi-year lows, the outlook has become more uncertain, and investors are questioning the quality of a business that was once viewed as one of the safest growth names on the ASX.
That is not comfortable. But I think the market may now be treating CSL as if its problems are structural and permanent. I do not see it that way.
CSL still owns world-class healthcare assets across plasma therapies, vaccines, and specialty medicines. It has a global scale, deep scientific capability, long-standing customer relationships, and exposure to markets where demand should keep growing over time.
The company clearly needs to rebuild trust. Guidance downgrades and execution issues are not easy to ignore. Management must prove that the business can return to more reliable growth, improve productivity, and restore confidence.
But if the current issues are largely short term, today's share price could end up looking too pessimistic.
That is why I would choose CSL shares over CBA for the next five years.
Foolish Takeaway
CBA may be a better business right now in terms of confidence and execution. But I think CSL may offer a better opportunity.
CBA still trades with a quality premium, even after its sell-off. That premium is understandable, but it may limit upside if earnings growth is steady rather than spectacular.
CSL is in a much more difficult place, but the share price already reflects a lot of disappointment.
If CSL stabilises, restores earnings momentum, and shows that its core healthcare franchises remain strong, I think the upside could be meaningful.
In other words, CBA looks like the safer buy. CSL looks like the more compelling recovery buy.
